Simultaneous Determination of Contezolid and Its Metabolite M2 in Human Plasma and Cerebrospinal Fluid by Ultra-High-Performance Liquid Chromatography – Tandem Mass Spectrometry (UHPLC-MS/MS)

References

• Anon. 2007. C50-A: CLSI Standards & Guidelines: Shop for CLSI Standards. Clinical & Laboratory Standards Institute.
   Google Scholar
• Anon. 2011. EMEA: Committee for medicinal products for human use, guideline on bioanalytical method validation.
   Google Scholar
• Anon. 2013. Bioanalytical method validation guidance for industry | FDA.
   Google Scholar
• Carvalhaes, C. G., L. R. Duncan, W. Wang, and H. S. Sader. 2020. In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against gram-positive clinical isolates from the United States and Europe. Antimicrobial Agents and Chemotherapy 64 (11):e01195-20. doi: 10.1128/AAC.01195-20.
   PubMed Web of Science ®Google Scholar
• Eckburg, P. B., Y. Ge, and B. Hafkin. 2017. Single- and multiple-dose study to determine the safety, tolerability, pharmacokinetics, and food effect of oral MRX-I versus linezolid in healthy adult subjects. Antimicrobial Agents and Chemotherapy 61 (4):e02181–16. doi: 10.1128/AAC.02181-16.
   PubMed Web of Science ®Google Scholar
• Gordeev, M. F., and Z. Y. Yuan. 2014. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. Journal of Medicinal Chemistry 57 (11):4487–97. doi: 10.1021/jm401931e.
   PubMed Web of Science ®Google Scholar
• Huang, Y., Y. Xu, S. Liu, H. Wang, X. Xu, Q. Guo, B. Wu, M. F. Gordeev, W. Wang, Z. Yuan, et al. 2014. Selection and characterisation of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I. International Journal of Antimicrobial Agents 43 (5):418–22. doi: 10.1016/j.ijantimicag.2014.02.008.
   PubMed Web of Science ®Google Scholar
• Jiang, J., Y. Hou, M. Duan, B. Wang, Y. Wu, X. Ding, and Y. Zhao. 2021. Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety. Bioorganic & Medicinal Chemistry Letters 32:127660. doi: 10.1016/j.bmcl.2020.127660.
   PubMed Web of Science ®Google Scholar
• Kaul, G., A. Dasgupta, and S. Chopra. 2022. Contezolid in complicated skin and soft tissue infection. Drugs of Today (Barcelona, Spain: 1998) 58 (7):315–26. doi: 10.1358/dot.2022.58.7.3389002.
   PubMed Web of Science ®Google Scholar
• Li, L., H. Wu, Y. Chen, H. Yuan, J. Wu, X. Wu, Y. Zhang, G. Cao, B. Guo, J. Wu, et al. 2020. Population pharmacokinetics study of contezolid (MRX-I), a novel oxazolidinone antibacterial agent, in Chinese patients. Clinical Therapeutics 42 (5):818–29. doi: 10.1016/j.clinthera.2020.03.020.
   PubMed Web of Science ®Google Scholar
• Lutsar, I., G. H. McCracken, Jr., and I. R. Friedland. 1998. Antibiotic pharmacodynamics in cerebrospinal fluid. Clinical Infectious Diseases 27 (5):1117–27. doi: 10.1086/515003.
   PubMed Web of Science ®Google Scholar
• Meng, J., D. Zhong, L. Li, Z. Yuan, H. Yuan, C. Xie, J. Zhou, C. Li, M. F. Gordeev, J. Liu, et al. 2015. Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: The oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metabolism and Disposition: The Biological Fate of Chemicals 43 (5):646–59. doi: 10.1124/dmd.114.061747.
   PubMed Web of Science ®Google Scholar
• Scaiola, A., M. Leibundgut, D. Boehringer, P. Caspers, D. Bur, H. H. Locher, G. Rueedi, and D. Ritz. 2019. Structural basis of translation inhibition by cadazolid, a novel quinoxolidinone antibiotic. Scientific Reports 9 (1):5634. doi: 10.1038/s41598-019-42155-4.
   PubMedGoogle Scholar
• Wang, S., C. Cai, Y. Shen, C. Sun, Q. Shi, N. Wu, S. Zheng, J. Qian, R. Zhang, and H. Zhou. 2021. In Vitro activity of contezolid against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, and strains with linezolid resistance genes from China. Frontiers in Microbiology 12:729900. doi: 10.3389/fmicb.2021.729900.
   PubMed Web of Science ®Google Scholar
• Wang, Y., H. Wu, J. Wu, Y. Fan, X. Liu, Y. Li, J. Hu, J. Zhang, and B. Guo. 2022. Development and validation of ultra-performance liquid chromatography-tandem mass spectrometric methods for simultaneous and rapid determination of contezolid and its major metabolite M2 in plasma and urine samples and its application to a study in subjects with moderate liver impairment. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 1191:123129. doi: 10.1016/j.jchromb.2022.123129.
   PubMed Web of Science ®Google Scholar
• Wu, J., G. Cao, H. Wu, Y. Chen, B. Guo, X. Wu, J. Yu, K. Ni, J. Qian, L. Wang, et al. 2020. Evaluation of the effect of contezolid (MRX-I) on the corrected QT interval in a randomized, double-blind, placebo- and positive-controlled crossover study in healthy chinese volunteers. Antimicrobial Agents and Chemotherapy 64 (6):e02158-19. doi: 10.1128/AAC.02158-19.
   PubMed Web of Science ®Google Scholar
• Wu, X., Y. Li, J. Zhang, Y. Zhang, J. Yu, G. Cao, Y. Chen, B. Guo, Y. Shi, J. Huang, et al. 2018. Short-term safety, tolerability, and pharmacokinetics of MRX-I, an oxazolidinone antibacterial agent, in healthy Chinese subjects. Clinical Therapeutics 40 (2):322–32.e5. doi: 10.1016/j.clinthera.2017.12.017.
   PubMed Web of Science ®Google Scholar
• Wu, X., J. Meng, H. Yuan, D. Zhong, J. Yu, G. Cao, X. Liu, B. Guo, Y. Chen, Y. Li, et al. 2021. Pharmacokinetics and disposition of contezolid in humans: Resolution of a disproportionate human metabolite for clinical development. Antimicrobial Agents and Chemotherapy 65 (11):e00409-21. doi: 10.1128/AAC.00409-21.
   PubMed Web of Science ®Google Scholar
• Zhang, G., N. Zhang, L. Dong, N. Bai, and Y. Cai. 2022. Development and validation of an LC-MS/MS method for the quantitative determination of contezolid in human plasma and cerebrospinal fluid. Pharmaceuticals 16 (1):32. doi: 10.3390/ph16010032.
   Web of Science ®Google Scholar
• Zhao, M., X. J. Wu, J. Huang, J. C. Yun, J. Zhang, and P. N. Guo. 2014. Development and validation of ultra-high performance liquid chromatography tandem mass spectrometry determination method of new oxazolidinone drug MRX-I in human plasma and urine concentration. Journal of Infection and Chemotherapy 14 (3):210–5.
   Google Scholar